NCT03815682 - RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

September 7, 2022

Study Completion Date

October 11, 2022

Conditions

Solid TumorLymphoma

Interventions

BIOLOGICAL

Arm A: RPTR-147:1

Escalating doses of RPTR-147:1 as a monotherapy

BIOLOGICAL

Arm B: RPTR-147:1 and Pembrolizumab

Escalating doses of RPTR-147:1 in combination with Pembrolizumab

BIOLOGICAL

Arm C: RPTR-147:2

Escalating doses of RPTR-147:2 in patients with HPV positive tumors

Trial Locations (7)

Carolina BioOncology Institute, Huntersville

Sarah Cannon Research Institute, Nashville

Karmanos Cancer Institute, Detroit

MD Anderson Cancer Center, Houston

City of Hope, Duarte

Yale Cancer Center, New Haven

Dana Farber Cancer Institute, Boston